Finding the best dose of remifentanil for inserting a laryngeal mask airway during anesthesia.
Dose Finding Study of Remifentanil for Laryngeal Mask Airway Insertion During Induction Using Remimazolam
This study is testing the best dose of remifentanil to help doctors successfully place a laryngeal mask airway in adults undergoing surgery with general anesthesia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 67 (estimated) |
| Ages | 19 Years to 64 Years |
| Sex | All |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06289829 on ClinicalTrials.gov |
What this trial studies
This study investigates the optimal dose of remifentanil to facilitate the insertion of the laryngeal mask airway (LMA) during general anesthesia induced by remimazolam. It involves adult patients scheduled for elective surgery, where the depth of anesthesia is crucial for successful LMA placement. The research employs a biased-coin up-and-down method to adjust the remifentanil dosage based on the success or failure of the insertion. Patients will be monitored using standard devices to ensure safety throughout the procedure.
Who should consider this trial
Good fit: Ideal candidates are adults aged 19 to 64 years, classified as ASA physical status I, II, or III, undergoing elective surgery with a duration of up to 3 hours.
Not a fit: Patients with a history of airway management difficulties, respiratory conditions, or those who are pregnant or obese may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the safety and effectiveness of anesthesia management during surgeries requiring airway support.
How similar studies have performed: Other studies have explored the use of remifentanil in anesthesia, but this specific approach to determine the optimal dosage for LMA insertion is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 19 years or older and less than 65 years * ASA physical status classification I, II, or III * Scheduled for elective surgery lasting within 3 hours under general anesthesia using a laryngeal mask Exclusion Criteria: * Refusal to participate in the study * Unable to read the consent form or comprehend the research process (e.g., illiteracy, foreign nationality, cognitive impairment) * Anatomic structures that are anticipated to cause difficulty in mask ventilation * History of difficulty in airway management * Upper respiratory infections or respiratory conditions (e.g., asthma, pneumonia) * Risk of aspiration (e.g., gastroesophageal reflux) * Allergies to anesthesia-related drugs, such as benzodiazepines or opioid analgesics * Impaired liver or kidney function * Pregnant or breastfeeding patients * Obesity (body mass index \> 30 kg/m2) * History of drug or alcohol abuse.
Where this trial is running
Seoul
- Severance Hospital — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Study coordinator: Darhae Eum, Assistant Clinical Professor
- Email: deum@yuhs.ac
- Phone: 82-2-2228-2431
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.